Issue link: https://viewer.e-digitaledition.com/i/111490
have concluded that a simple blood test may screen for individuals carrying increased cancer risk. Until now, only four clinical factors were known to predict an inherited PTEN mutation ��� and this study���s blood test out-predicts them all. Future studies testing thyroid tissue itself may reveal additional biomarkers. potential Drug for alzheimer���s Disease A compound developed to treat neuropathic pain has shown potential as an innovative treatment for Alzheimer���s disease, according to a study by researchers at Cleveland Clinic���s Lerner Research Institute and Anesthesiology Institute. ���Cleveland Clinic dedicated two years of research into the examination of this compound and our findings show it could represent a novel therapeutic target in the treatment of Alzheimer���s disease,��� says Mohamed Naguib, MD, Professor of Anesthesiology, Cleveland Clinic Lerner College of Medicine. ���Development of this compound as a potential drug for Alzheimer���s would take many more years, but this is a promising finding worthy of further investigation.��� In a study published online in the Neurobiology of Aging, the compound MDA7 induced beneficial immune responses that limited the development of Alzheimer���s disease. Treatment with the compound restored cognition, memory and synaptic plasticity ��� a key neurological foundation of learning and memory ��� in an animal model. Neuroinflammation is an important mechanism involved in the progression of Alzheimer���s disease. The MDA7 compound has anti-inflammatory properties that act on the CB2 receptor ��� one of the two cannabinoid receptors in the body ��� but without the negative side effects normally seen with cannabinoid compounds. Dr. Naguib is named on two patent applications on CB2 modulators submitted by the University of Texas MD Anderson Cancer Center. ��� Brouse McDowell adds value to your health care business. The health care industry constantly faces new and complex challenges. Brouse McDowell���s health care law practice group proactively counsels and advises a wide array of health care clients, including multi- and single-physician groups, hospitals, health systems, ancillary service providers, long term care facilities, medical device companies and durable medical equipment and supply companies. For more information, please contact: Daniel K. Glessner, Esq., Practice Chair 330.535.5711 x316 dglessner@brouse.com or Christopher M. Huryn, Esq. 330.535.5711 x389 churyn@brouse.com Collective Experience. Collaborative Culture. Creative Solutions. Akron ��� Cleveland ��� Avon ��� www.brouse.com MarcH -april 2013 ��� MDneWS.coM ��� MD News Cleveland/Akron/Canton | 27